CRIS Current Research Information System

MARINELLI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.090
AS - Asia 1.920
EU - Europa 1.324
AF - Africa 145
SA - Sud America 89
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 1
Totale 5.585
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.069
VN - Vietnam 730
SG - Singapore 472
CN - Cina 380
IT - Italia 278
GB - Regno Unito 241
SE - Svezia 192
DE - Germania 174
HK - Hong Kong 113
FR - Francia 84
IN - India 75
NL - Olanda 63
BR - Brasile 59
RU - Federazione Russa 56
IE - Irlanda 51
FI - Finlandia 40
ZA - Sudafrica 40
TG - Togo 35
JP - Giappone 34
UA - Ucraina 34
SC - Seychelles 31
CH - Svizzera 23
PH - Filippine 18
EE - Estonia 17
BG - Bulgaria 16
CA - Canada 16
CI - Costa d'Avorio 15
EU - Europa 15
JO - Giordania 14
KR - Corea 14
TH - Thailandia 14
AR - Argentina 10
AT - Austria 10
BE - Belgio 10
ID - Indonesia 9
NG - Nigeria 9
PL - Polonia 9
ES - Italia 8
IQ - Iraq 7
TW - Taiwan 7
BD - Bangladesh 6
CL - Cile 6
LT - Lituania 6
TR - Turchia 6
CO - Colombia 5
MX - Messico 5
PY - Paraguay 5
MA - Marocco 4
MY - Malesia 4
UZ - Uzbekistan 4
HR - Croazia 3
PE - Perù 3
PK - Pakistan 3
SN - Senegal 3
DZ - Algeria 2
GH - Ghana 2
GR - Grecia 2
KE - Kenya 2
LV - Lettonia 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
GE - Georgia 1
HU - Ungheria 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MK - Macedonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.585
Salva come PNG Salva come JPEG
Città #
Singapore 338
Ashburn 248
Dong Ket 217
Southend 214
Fairfield 209
Chandler 185
Ho Chi Minh City 149
Hanoi 116
San Jose 116
Hong Kong 101
Seattle 99
Wilmington 91
Woodbridge 87
Houston 79
Bologna 71
Santa Clara 64
Princeton 56
Cambridge 54
Dublin 51
Ann Arbor 50
Los Angeles 44
Boardman 40
Beijing 35
Lauterbourg 35
Lomé 35
Helsinki 32
Dallas 28
Da Nang 27
Tokyo 27
Padova 24
New York 22
Westminster 22
Dearborn 21
Frankfurt am Main 21
Berlin 20
Bern 20
Nanjing 20
Council Bluffs 18
Haiphong 18
Hefei 18
Jinan 18
Sofia 16
Abidjan 15
Munich 15
Amman 13
Guangzhou 13
Johannesburg 13
Saint Petersburg 13
Turin 13
Nanchang 12
Buffalo 11
Chicago 11
Jacksonville 11
Redondo Beach 11
Shanghai 11
Amsterdam 10
Brussels 10
Düsseldorf 10
Abeokuta 9
Changsha 9
Florence 9
Phoenix 9
Seoul 9
San Diego 8
Shenzhen 8
Tianjin 8
Toronto 8
Bangkok 7
Des Moines 7
Hangzhou 7
Milan 7
Bühl 6
Bến Tre 6
Catanzaro 6
Hebei 6
Medford 6
Nuremberg 6
Shenyang 6
Thái Bình 6
Warsaw 6
Atlanta 5
Bremen 5
Falkenstein 5
Jakarta 5
Kunming 5
Olalla 5
Orem 5
Paris 5
Redwood City 5
Sassari 5
Turku 5
Vienna 5
Xi'an 5
Zhengzhou 5
Bắc Giang 4
Long Xuyen 4
Montreal 4
Ningbo 4
Rio de Janeiro 4
Rome 4
Totale 3.601
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 277
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 257
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma 250
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 239
Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. 237
Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study 235
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 223
Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? 218
Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. 211
Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma 207
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry 194
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma 193
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study 175
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. 173
Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients 171
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 170
Early Prediction of Treatment Response to Sorafenib with Elastosonography in a Mice Xenograft Model of Hepatocellular Carcinoma: A Proof-of-Concept Study. 167
null 164
The role of ultrasound elastographic techniques in chronic liver disease: current status and future perspectives 158
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study 157
Experience with regorafenib in the treatment of hepatocellular carcinoma 147
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 141
Erratum to: Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry (Intern Emerg Med, 10.1007/s11739-016-1416-8) 132
Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. 129
Ipertensione portale. 128
Letter to the editor. 126
The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. 111
Sorafenib versus Y90 radioembolization in cirrhotic patients with hepatocellular carcinoma (HCC): cohort and nested control-case study with propensity analysis 87
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib 84
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC 82
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 77
null 77
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 70
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 58
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 54
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 51
Neutrophil–lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry 42
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma 34
Totale 5.706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.540
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.540
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021280 0 0 0 0 0 0 0 0 0 24 16 240
2021/2022612 61 14 24 62 51 33 12 32 18 44 181 80
2022/2023669 79 105 27 94 35 68 16 26 114 14 46 45
2023/2024194 24 25 12 20 15 47 11 4 13 13 6 4
2024/2025629 23 70 73 61 97 32 41 27 10 64 20 111
2025/20262.137 164 133 137 135 244 143 323 144 561 153 0 0
Totale 5.706